RecruitingNCT06599619
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Studying Familial atypical multiple mole melanoma syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- John Kirkwood
- Principal Investigator
- John M Kirkwood, MDUPMC Hillman Cancer Center
- Intervention
- Single agent, adjuvant anti-PD1 therapy(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Collaborators
Melanoma Research Foundation · VeyTel Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06599619 on ClinicalTrials.govOther trials for Familial atypical multiple mole melanoma syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT04095195Registry of Subjects at Risk of Pancreatic CancerAssociazione Italiana per lo Studio del Pancreas
- RECRUITINGNCT05446155BioMEL- Diagnostic and Prognostic Factors in Melanoma.Region Skane
- RECRUITINGNCT00040352Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaNational Cancer Institute (NCI)
See all trials for Familial atypical multiple mole melanoma syndrome →